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Abstract An important role has been attributed to cancer-
associated fibroblasts (CAFs) in the tumorigenesis of oral
squamous cell carcinoma (OSCC), the most common tumor
of the oral cavity. Previous studies demonstrated that CAF-
secreted molecules promote the proliferation and invasion of
OSCC cells, inducing a more aggressive phenotype. In this
study, we searched for differences in the secretome of CAFs
and normal oral fibroblasts (NOF) using mass spectrometry-
based proteomics and biological network analysis. Compari-
son of the secretome profiles revealed that upregulated pro-
teins involved mainly in extracellular matrix organization and
disassembly and collagen metabolism. Among the upregulat-
ed proteins were fibronectin type III domain-containing 1
(FNDC1), serpin peptidase inhibitor type 1 (SERPINE1),
and stanniocalcin 2 (STC2), the upregulation of which was
validated by quantitative PCR and ELISA in an independent
set of CAF cell lines. The transition of transforming growth
factor beta 1 (TGF-β1)-mediating NOFs into CAFs was ac-
companied by significant upregulation of FNDC1,
SERPINE1, and STC2, confirming the participation of these
proteins in the CAF-derived secretome. Type I collagen, the
main constituent of the connective tissue, was also associated
with several upregulated biological processes. The
immunoexpression of type I collagen N-terminal propeptide
(PINP) was significantly correlated in vivo with CAFs in the
tumor front and was associated with significantly shortened
survival of OSCC patients. Presence of CAFs in the tumor
stroma was also an independent prognostic factor for OSCC
disease-free survival. These results demonstrate the value of
secretome profiling for evaluating the role of CAFs in the
tumor microenvironment and identify potential novel thera-
peutic targets such as FNDC1, SERPINE1, and STC2. Fur-
thermore, type I collagen expression by CAFs, represented by
PINP levels, may be a prognostic marker of OSCC outcome.
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Introduction
Oral squamous cell carcinoma (OSCC) is the eleventh most
common solid tumor worldwide, representing about 4 % of all
malignancies [1]. The World Health Organization (WHO) es-
timated for 2012 approximately 685,000 new cases of head
and neck cancer, with the oral cavity as the most frequent site
with 300,000 cases and 145,000 deaths [1]. Despite advances
in research and treatment options, especially with new chemo-
therapy drugs, the prognosis of patients with OSCC has
remained virtually unchanged over recent decades, remaining
at 50 % over 5 years [2]. This low survival rate is attributed
mainly to late diagnosis, poor response to chemotherapy and
radiotherapy, and insufficient biomarkers for early diagnosis
and post-therapeutic monitoring [3].
During the process of invasion, tumor cells are able to
induce a series of changes characterized by the accumulation
of inflammatory and immune cells, blood and lymphatic cap-
illaries, components of the extracellular matrix, fibroblasts,
and myofibroblasts (also called cancer-associated fibroblasts
(CAFs), comprising the tumor microenvironment [4]. There is
evidence that all components of the tumor stroma can critical-
ly influence carcinogenesis and the malignant phenotype in
multiple stages of tumor development [5, 6]. Among these
components, CAFs, fibroblast-like cells that acquire the abil-
ity to express isoform α of the smooth muscle actin (α-SMA)
and synthesize an extensive repertoire of cytokines, growth
factors, chemokines, hormones, neurotransmitters, inflamma-
tory mediators, adhesion proteins, and most abundantly extra-
cellular matrix proteins, have been highlighted as the major
player in tumor-stroma cross talk [7].
CAFs contribute significantly to important hallmarks nec-
essary for cancer progression such as invasion and metastasis,
immune escape, inflammation, angiogenesis, and sustained
growth [8–10]. The presence of these cells is also associated
with poor prognosis in numerous tumor types, including
OSCCs [11–17]. Identifying proteins synthesized by CAFs
is crucial for a better understanding of the biological events
associated with oral tumorigenesis and for the discovery of
new tumor biomarkers, enabling, for example, discrimination
of patients at high and low risk of developing metastasis and
allowing for more individualized treatment. Previous studies
have already identified proteins secreted by CAFs in colorec-
tal [18, 19], head and neck cancer [20], and nasopharyngeal
cancer [21]. In a previous study, we demonstrated that CAFs
promote tumorigenesis of oral tongue SCC cell lines via se-
cretion of high levels of activin A, a member of the
transforming growth factor-β superfamily of proteins [8].
CAFs also secrete various types of collagen, which may lead
to tumor growth, invasion, and spread. Interestingly, the re-
lease of the N-terminal propeptide of type I collagen (PINP)
was associated with the poor prognosis of oral tongue SCC
patients [22].
Aiming to identify proteins released by CAFs, the pres-
ent study compared the secretome derived from CAFs
isolated from OSCCs with the secretome of fibroblasts
isolated from normal oral mucosa. The expression levels
of fibronectin type III domain-containing protein 1
(FNDC1), serpin peptidase inhibitor type 1 (SERPINE1,
also called plasminogen activator inhibitor-1), and
stanniocalcin 2 (STC2) in the CAF secretome were sig-
nificantly higher, enhancing our understanding of the reg-
ulatory mechanisms of CAFs in the microenvironment of
OSCCs. Biological processes associated with type I col-
lagen expression were overrepresented in CAFs, and high
immunoexpression levels of both PINP and α-SMA
(representing CAF density) in the tumor invasive front
were associated with a worse prognosis for OSCC
patients.
Material and methods
Clinical samples and cell culture
The study was approved by the Human Research Ethics Com-
mittee of the School of Dentistry, University of Campinas,
Brazil (protocol number 090/2011). After informed consent
was given, samples were taken from OSCC patients and from
patients with healthy oral mucosa without history of exposure
to risk factors related to OSCC, such as smoking and alcohol
consumption. The patients (six males and one female) were
diagnosed with OSCC with a histological grade of well-
differentiated (two cases) and moderately differentiated (five
cases). Each tumor sample was obtained in the central area of
the lesion, avoiding necrotic areas, and divided in two parts:
One was fixed in formalin and embedded in paraffin for he-
matoxylin and eosin staining, while the other was washedwith
phosphate-buffered saline (PBS), incubated in Dulbecco’s
modified Eagle’s media (DMEM, Invitrogen, USA) supple-
mented with 10 % calf serum (Invitrogen, USA) and antibi-
otics, and immediately processed. Normal oral mucosa was
obtained from four males and three females and processed the
same way.
Normal oral fibroblast (NOF) and CAF cell lines were
established using tissue explants and characterized as de-
scribed previously [23]. The secretome was initially investi-
gated by mass spectrometry analysis, and proteins showing a
significantly higher expression in CAFs compared to NOFs
were subsequently validated in an independent set of six NOF
cell lines and six CAF cell lines.
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Sample preparation for liquid chromatography associated
with mass spectrometry
One cell line of each group (NOF-1 and CAF-1) plated at
80 % confluence (three 100-mm2 dishes per condition per
experiment) were gently washed with PBS and incubated
in a serum-free media for 24 h at 37 °C. After collection
of the conditioned media, ethylenediaminetetraacetic acid
(EDTA) and phenylmethylsulfonyl fluoride (PMSF) were
added at a final concentration of 1 mM. Cell debris and
intact cells were eliminated by centrifugation, and the
conditioned media were concentrated using a 3000-Da
centrifugal filter (Amicon Ultra, Millipore, Ireland) at
4 °C. Protein concentrations were determined using a pro-
tein assay according to the manufacturer’s instructions
(Bio-Rad Protein Assay, Bio-Rad, USA). Proteins
(80 μg) were treated with a final concentration of 1.6 M
urea, following reduction (5 mM dithiothreitol, 25 min at
56 °C), alkylation (14 mM iodoacetamide, 30 min at room
temperature in the dark), and digestion with trypsin (1:50,
w/w). The reaction was stopped with 1 % trifluoroacetic
acid (TFA) and desalted with Sep-Pack cartridges. The
samples were dr ied in a vacuum concent ra tor,
reconstituted in 0.1 % formic acid, and analyzed by liquid
chromatography associated with mass spectrometry (LC-
MS/MS). Three independent experiments were performed
for each cell line.
LC-MS/MS analysis
An aliquot containing 3 μg of proteins was analyzed on an
ETD-enabled LTQ Orbitrap Velos Mass Spectrometer (Ther-
mo Fisher Scientific, USA) connected to a nanoflow liquid
chromatography column (LC-MS/MS) by an EASY-nLC Sys-
tem (Proxeon Biosystem) through a proxeon nanoelectrospray
ion source. Peptides were separated by a 2–90 % acetonitrile
gradient in an analytical PicoFrit column (20 cm× id 75 μm,
5-μm particle size, New Objective) at a flow of 300 nl/min
over 212 min. The nanoelectrospray voltage was set to 2.2 kV,
and the source temperature was 275 °C. All instrument
methods for the LTQ Orbitrap Velos were set up in the data-
dependent analysis (DDA) mode. The full-scan MS spectra
(m/z 300–1600) were acquired in the Orbitrap analyzer after
accumulation to a target value of 1e6. The resolution in the
Orbitrap was set to r=60,000. The 20 most intense peptide
ions with charge states ≥2 were sequentially isolated to a target
value of 5000 and fragmented in the linear ion trap by low-
energy CID (normalized collision energy of 35 %). The signal
threshold for triggering an MS/MS event was set to 1000
counts. Dynamic exclusion was enabled with an exclusion
size list of 500, an exclusion duration of 60 s, and a repeat
count of 1. An activation q=0.25 and an activation time of
10 ms were used.
Protein identification and quantitative analysis
The raw files were processed using the MaxQuant version
1.2.7.429, and the MS/MS spectra were searched using the
Andromeda search engine against the Uniprot Human Protein
Database (release July 11, 2012; 69,711 entries). The initial
maximal allowed mass tolerance was set to 20 ppm for pre-
cursor and then set to 6 ppm in the main search and to 0.5 Da
for fragment ions. Enzyme specificity was set to trypsin with a
maximum of twomissed cleavages. Carbamidomethylation of
cysteine (57.021464 Da) was set as a fixed modification, and
oxidation of methionine (15.994915 Da) and protein N-
terminal acetylation (42.010565 Da) were selected as variable
modifications. The minimum peptide length was set to 6 ami-
no acids. Bioinformatic analyses were performed using Per-
seus v.1.2.7.4,29, which is available in the MaxQuant envi-
ronment. First, reverse and contaminant entries were excluded
from further analysis. Label-free quantificationwas performed
using the normalized spectral protein intensity (LFQ intensi-
ty). Data obtained from three independent experiments from
each cell line were annotated, and for the analysis of differen-
tially expressed proteins, the data were converted into log2
and Student’s t test was applied.
Quantitative PCR
Quantitative PCR (qPCR) was used for validation of six pro-
teins identified in the LC-MS/MS with significantly higher
levels (more than twofold) in CAF-1 cells compared to
NOF-1 cells. Total RNA was isolated with the RNeasy mini
kit (Qiagen, USA) according to the manufacturer’s protocols.
Following DNase I treatment, in order to eliminate genomic
DNA contamination, 1 μg of total RNA per sample was used
to generate complementary DNA (cDNA) using Oligo-dT
(Invitrogen, USA) and a superscript enzyme (Superscript II
RT enzyme, Invitrogen, USA). The resulting cDNAs were
subjected to qPCR using SYBR Green PCR Master Mix (Ap-
plied Biosystems, USA) in the StepOnePlus Real-Time PCR
System (Applied Biosystems, USA). Gene expression was
determined using the delta-delta CT method, and the house-
keeping gene PPIA (cyclophilin A) was used as reference
gene for data normalization. All reactions were performed in
triplicate. Pairs of primers are described in Supplementary
Table 1.
Enzyme-linked immunosorbent assay
The production of the proteins validated in the qPCR
(FNDC1, SERPINE1 and STC2) as significantly higher in
CAFs compared to NOFs were also assessed by enzyme-
linked immunosorbent assay (ELISA). To obtain conditioned
cell culture media, cells were plated in 24-well culture plates at
a density of 80,000 cells/well in DMEM containing 10 % of
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calf serum. After 24 h, the cells were rinsed with PBS and the
media replaced by DMEMwithout serum. After another 24 h,
the media of each well was collected and concentrated using a
3000-Da centrifugal filter (Sartorius Stedim Biotech, Germa-
ny). Levels of SERPINE1 were analyzed with a human
ELISA Kit SimpleStep (Abcam, USA) according to the man-
ufacturer’s protocol. For FNDC1 and STC2, plates were coat-
ed with the concentrated samples for 2 h at room temperature
and non-specific binding sites were blocked with 3 % BSA in
PBS for 2 h. After washing, anti-FNDC1 antibody (clone Y-
12, Santa Cruz Biotechnology, USA), diluted 1:3000, and
anti-STC2 antibody (Abcam, USA), diluted 1:1000, were
added to the wells and incubated for 2 h. After washing step,
donkey anti-goat IgG horseradish peroxidase (HRP)-conju-
gated (Santa Cruz Biotechnology, USA), diluted 1:5000 (for
FNDC1), and goat anti-rabbit IgG conjugated to HRP
(Abcam, USA), diluted 1:10,000 (for STC2), were added
and maintained for 1 h. The reactions were developed with
TMB substrate reagent set BD OptEIA (Becton Dickinson)
according to the manufacturer’s protocol. After terminating
the reaction with 2 N H2SO4, absorbance was read at
450 nm with correction at 650 nm. Standard curves were
constructed for FNDC1 (Santa Cruz Biotechnology, USA),
ranging from 62.5 to 2000 pg/ml, and STC2 (Abcam, USA),
ranging from 0.37 to 46.88 pg/ml. The wells of replicate plates
were treated in a similar manner and used for cell counts. Cells
were harvested using 0.2 % trypsin and counted with a cell
counter (Countess Automated Cell Counter, Invitrogen,
USA). The values were expressed as nanograms of protein
per cell.
Treatment of NOF with TGF-β1
Lyophilized transforming growth factor beta 1 (TGF-β1)
(R&D Systems, USA) was dissolved in culture media,
aliquoted, and stored at −80 °C. To assess the effect of this
cytokine, NOF cell lines were cultured in 0.1 % of calf serum
media containing 10 ng/ml of TGF-β1 for 48 h [24].
Immunohistochemistry
Immunohistochemical analysis was performed in a cohort
composed of 113 patients with primary OSCC, who were
diagnosed and treated at two reference hospitals in Cascavel,
state of Paraná, Brazil: the Oncology Center of Cascavel
(CEONC, n=46 patients) and the UOPECCAN Cancer Hos-
pital (n=67 patients) from 1998 to 2008. The clinicopatho-
logical features of this cohort were recently described [25].
PINP and α-SMA immunostaining was performed using
the streptavidin-biotin peroxidase complex method. Briefly,
after dewaxing and hydration in graded alcohol solutions,
the sections were treated with 3 % H2O2 followed by antigen
retrieval with 10 mM citric acid pH 6.0 in a pressure cooker.
After washing with PBS, the sections were treated with 1 %
bovine serum albumin (BSA) in PBS for 1 h and then incu-
bated with polyclonal rabbit anti-human antibody against
PINP [26], diluted 1:5000, or monoclonal mouse anti-human
antibody against α-SMA (clone 1A4, Dako, USA). Reactions
were developed by incubating the sections with 0.6 mg/ml 3,
3′-diaminobenzidine tetrahydrochloride (Sigma-Aldrich,
USA) containing 0.01 % H2O2. Control reactions were per-
formed by omission of the primary antibody.
α-SMA-positive cells (CAFs) were assessed as described
by Kellermann et al. [11]. Tumors lacking α-SMA-positive
cells were classified as negative, scanty if more than 1 % and
less than 50% of the stromal cells wereα-SMA positives, and
abundant if more than 50% of the stromal cells were α-SMA-
positive cells. The percentage of PINP-positive cells in the
stromal cells in both the stroma within the tumor (designed
overall area for the purposes of this study) and the deep inva-
sive tumor front (defined as tumor front, which represents the
band of tissue between the invasive tumor front and adjacent
normal tissue) were scored as low (negative samples and sam-
ples up to 50 % of positive cells) and high (more than 50 % of
positive cells) expression.
Statistical analysis
All in vitro assays were performed at least three times. For
those assays, Mann-Whitney U test or one-way analysis of
variance (ANOVA) with post hoc comparisons based on the
Tukey’s multiple comparison test were applied, and the p val-
ue of 0.05 was set as statistically significant.
For statistical purposes, samples classified as negative or
scanty density of CAFs were grouped together and compared
with samples with abundant presence of CAFs. Correlations
between clinicopathological parameters of the tumors and im-
munohistochemical analyses were performed using
Spearman’s rank correlation. Survival curves were construct-
ed based on the Kaplan-Meier method and compared with the
log-rank test. For multivariate survival analysis, the Cox pro-
portional hazard model with a stepwise method was
employed.
Results
To characterize NOF and CAF cell lines, α-SMA expression
was assessed by qPCR. In this specific analysis, we used a
pool of seven NOFs as a reference. All CAF cell lines showed
at least a twofold increase in α-SMA messenger RNA
(mRNA) levels compared to the reference pool (Fig. 1a). Im-
munocytochemical analysis demonstrated strong cytoplasmic
staining for α-SMA in the CAF cell lines, which was not
observed in the NOF cells (Fig. 1b). Immunoreactivity for
vimentin was detected in 100 % of both NOF and CAF cells,
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whereas cells were negative for pan-cytokeratin and CD34
marker (Fig. 1b).
Secreted proteins were collected from one NOF (NOF-1)
and one CAF (CAF-1) cell line, digested with trypsin, and the
resulting peptides were analyzed in independent triplicates via
LC-MS/MS. Using normalized spectral protein intensity
(LFQ intensity) in the MaxQuant software, accepting only
peptide and protein identifications with an FDR better than
0.01, we identified 271 proteins (Supplementary Table 2).
The log2 values of the expressed proteins were normalized
by Z-score and represented in the heat map, which grouped
the triplicates of each cell line together (Fig. 2). Combining
Student’s t test and a fold-change of 2, applied in log2 LFQ
intensity values, we identified 13 upregulated and 5 downreg-
ulated proteins in CAF cells (Table 1).
Functional annotation analysis of proteins identified in the
two cell types was performed using all differentially expressed
proteins (Supplementary Table 3). For that purpose, we used
the ClueGO plugin v2.0.6within Cytoscape v.3.0.1 for enrich-
ment analysis and classified the proteins according to GO
terms for biological processes and cellular components. The
most significantly CAF overrepresented GO terms were ex-
tracellular matrix organization (GO 0030198, corrected p
value = 3.21E-37), extracellular matrix disassembly (GO
0022617, corrected p value=1.31E-17), and collagen meta-
bolic process (GO 0032963, corrected p value=2.19E-8). In
this context, we were able to relate those proteins that were
found to be most significantly overrepresented in CAFs in
Fig. 1 Characterization of CAF cell lines. a The levels of α-SMA
mRNA in CAF and NOF cell lines were assessed by quantitative PCR.
For comparison, expression in CAFs was normalized to the average value
of the NOF cells. Data showed a clear overexpression above twofold in all
CAF cell lines. b Immunocytochemistry analysis of markers of cell
differentiation. CAFs demonstrated a vivid cytoplasmatic staining for
α-SMA, which was not observed in NOFs. Immunoreactivity for
vimentin was detected in both NOF and CAF cells, and both cells were
negative to pan-cytokeratin and CD34. Representative images of one
NOF (NOF-1) and one CAF (CAF-1) cell lines are shown here
(original magnification ×100)
Fig. 2 Heat map of the differentially expressed proteins in NOF and
CAF cells. Proteins identified in NOF-1 and CAF-1 cell lines were
hierarchically clustered by using the Z-score LFQ values with
MaxQuant software. This cluster analysis revealed clear differences
between NOF and CAF cells
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comparison with NOF cells, including FNDC1, SERPINE1,
STC2, elastin (ELN), matrix metallopeptidase 3 (MMP3), and
xylosyltransferase 1 (XYLT1), to extracellular matrix organi-
zation and disassembly.
To confirm the higher expression of those six proteins in
CAFs compared to NOFs, we performed qPCR analysis
followed by ELISA. A consistent and significant overexpres-
sion of FNDC1, SERPINE1, and STC2 was observed across
the different CAF cell lines compared to controls (difference
between groups p = 0.01 for FNDC1, p = 0.0006 for
SERPINE1, p=0.001 for STC2), whereas overexpression of
ELN, MMP-3, and XYLT1 was identified in a few CAF cell
lines, revealing no significant differences between groups
(Fig. 3). In this specific analysis, we used a pool of six NOFs
as a reference. Significantly higher levels of FNDC1 (p=0.01),
SERPINE1 (p=0.005), and STC2 (p=0.02) were also ob-
served in CAFs compared to NOFs in the ELISA (Fig. 4).
Stimulation of NOF cell lines with TGF-β1 was performed to
induce CAF activation as previously described [24]. Treatment
with TGF-β1 significantly induced the expression of α-SMA
(Supplementary Fig. 1), which was followed by significant up-
regulation of FNDC1, SERPINE1, and STC2 (Fig. 5).
Several biological processes overrepresented in CAFs were
associated with collagen anabolism and catabolism. Thus, to
further evaluate the relevance of type collagen I expression
originating from CAFs to OSCC, immunohistochemical anal-
ysis of both α-SMA, characterizing CAFs, and PINP was
performed. Immunohistochemical reaction for α-SMA
showed CAF-positive cells in 91.4 % of OSCCs. CAFs were
located in close contact with neoplastic islands, and areas of
tumor-free stroma demonstrated a complete lack of CAFs. All
samples demonstrated positivity for α-SMA in the smooth
muscle of the blood vessel walls, which worked as an internal
positive control. Interestingly, PINP was observed as a cyto-
plasmic stain with variable distribution and intensity in both
tumor and stromal cells. Many CAF cells were reactive for the
antibody anti-PINP (Fig. 6), and a significant correlation be-
tween CAF density and PINP expression in the invasive front
was detected (Table 2). The clinicopathological correlations
with the presence of CAFs and the expression of PINP in the
stromal cells are depicted in Table 3. A significant correlation
between PINP immunoexpression in the overall tumor stroma
and age was observed in this cohort (p=0.002). Significant
correlations were also observed between the density of CAFs
in the overall stroma (p=0.007) and invasive front stroma
(p=0.003) and type of treatment and between the presence
of CAFs in the invasive front and the development of a second
primary tumor (p=0.05).
Increased PINP expression by stromal cells in both overall
stroma (p=0.005) and invasive front (p=0.005) was associ-
ated with shortened specific survival (Fig. 7). Abundant pres-
ence of CAFs in the invasive front was also significantly as-
sociated with lower specific survival (p=0.006, Fig. 7). Pa-
tients whose tumors showed high expression of PINP in the
stromal cells in the invasive front had a significantly shorter
disease-free survival period than patients with low expression
Table 1 Upregulated and downregulated proteins identified in the secretome of CAFs
Protein Abbreviation Ratio p Value
Upregulated Fibronectin type III domain-containing protein 1 FNDC1 4.83 0.0001
Insulin-like growth factor-binding protein 3 IGFBP3 4.82 0.0003
Cartilage oligomeric matrix protein COMP 4.57 0.0012
Elastin ELN 3.54 0.007
Collagen alpha-1(VII) chain COL7A1 3.35 0.006
Stromelysin-1 MMP3 3.23 0.0002
Transforming growth factor-beta-induced protein ig-h3 TGFBI 2.97 0.002
Plasminogen activator inhibitor 1 SERPINE1 2.59 0.0006
Xylosyltransferase 1 XYLT1 2.53 0.011
Collagen alpha-1(V) chain COL5A1 2.39 0.002
Stanniocalcin-2 STC2 2.39 0.005
Latent-transforming growth factor beta-binding protein 2 LTBP2 2.28 0.001
Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 PLOD2 2.13 0.003
Downregulated Tetranectin CLEC3B −5.23 0.0004
Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 ENPP2 −4.75 0.001
Collagen alpha-1(XIV) chain COL14A1 −3.43 0.002
Insulin-like growth factor-binding protein 5 IGFBP5 −3.20 0.009
Laminin subunit beta-2 LAMB2 −2.17 0.0008
Values represent the fold of expression in CAFs in relation to NOFs
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(p=0.02, Fig. 8). Similarly, patients with tumors showing
negative/scanty presence of CAFs had longer disease-free sur-
vival than those with tumor showing abundant presence, in
both overall (p= 0.03) and invasive front (p= 0.01) areas
(Fig. 8).
The adjusted multivariate analysis based on Cox propor-
tional regression found that expression of PINP by the stromal
cells at the invasive front was a significant predictor of
disease-specific and disease-free survival of patients with
OSCC (Table 4). Hazard ratios (HRs) of 3.31 (95 % CI
1.54–5.96, p=0.002) for specific survival and 3.78 (95 % CI
1.22–11.67, p=0.02) for disease-free survival were observed.
Presence of CAFs significantly influenced relapse (disease-
free survival) of OSCC patients. For overall distribution of
Fig. 3 FNDC1, SERPINE1, and
STC2 are overexpressed in CAF
cell lines. Expression analysis of
FNDC1, ELN, SERPINE1,
MMP-3, XYLT1, and STC2,
which were identified in the LC-
MS/MS with significantly higher
levels (more than twofold) in
CAF-1 cells compared to NOF-1
cells, were verified by
quantitative PCR in six different
cell lines of NOF and six of
CAFs. Higher levels of FNDC1,
SERPINE1, and STC2 were
observed across the different CAF
cell lines compared to control.
ELN, MMP-3, and XYLT1
overexpressions were not
confirmed in this set of CAFs.
*p< 0.05, **p< 0.01,
***p< 0.005, ****p< 0.001
Fig. 4 Validation of the higher levels of FNDC1, SERPINE1, and STC2
in CAF cell lines. Proteins secreted by NOFs and CAFs were collected
and subjected to ELISA using specific antibodies against FNDC1,
SERPINE1, and STC2. Data are expressed as nanograms of protein/
cell. The amount of FNDC1, SERPINE1, and STC2 produced by CAF
cells was significantly higher than NOF cells
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CAFs, a HR of 2.99 (95%CI 1.52–5.92, p=0.002) was found
for abundant presence in relation to negative/scanty presence.
Similarly, abundant presence of CAFs in the invasive front
revealed a HR of 3.08 (95 % CI 1.61–5.92, p=0.0001). Cox
analysis of specific survival also revealed that N stage is an
independent prognostic factor of this OSCC cohort.
Discussion
Stromal cells in the tumor microenvironment, including lym-
phocytes, macrophages, endothelial cells, and active fibro-
blasts, have been shown to influence the aggressiveness of
cancer cells by inducing invasion and metastasis [4]. This
functional state of tumor-associated cells holds a wealth of
prognostic and response-predictive information and opens
up novel options for stroma-based anticancer therapies. CAFs,
which indicate myofibroblast transdifferentiation, seem to be
especially critical for many aspects of oral carcinogenesis,
since the presence of CAFs, mainly in the invasive front, de-
notes a more aggressive phenotype by promoting the prolifer-
ation and invasion of tumor cells [8, 11, 27]. However, efforts
to develop new treatments targeting CAFs are complicated by
our poor understanding of the mechanisms underlying their
development and by only partial knowledge of their
mechanisms of induction of OSCCs. Thus, knowledge of
CAF secretome signatures may help determine the contribu-
tion of this specific cell type to the complex profile of OSCCs.
Herein, we analyzed the LFQ proteomic data and identified
the secretome signatures of OSCC-derived CAFs. In this way,
we were able to characterize the functional state of CAFs and
to identify proteins that may be related to the supportive ef-
fects of CAFs in tumor cell invasion and metastasis.
CAFs may exchange cytokines, extracellular matrix pro-
teins, and enzymes that promote growth directly through the
stimulation of proliferation and survival, as well as invasion
via local proteolysis of the extracellular matrix [7, 28]. In fact,
we identified several proteins related to extracellular matrix,
and the GO terms extracellular matrix organization, extracel-
lular matrix disassembly, and collagenmetabolic process were
overrepresented in the secretome of CAFs in comparison with
NOFs. Among the proteins upregulated in CAFs and associ-
ated with these biological processes are FNDC1, SERPINE1,
and STC2. Those three proteins were validated by qPCR and
ELISA in different CAF cell lines and in the model character-
ized by TGF-β1 stimulating normal fibroblast transition to
CAFs.
Recently, attention has been paid to the fibronectin type III
domain-containing proteins, but our understanding of their roles
in normal and pathological conditions is limited. These proteins
Fig. 5 TGF-β1-induced CAF activation is associated with the
production of higher levels of FNDC1, SERPINE1, and STC2. NOF
cells were cultured in the presence of 10 ng/ml of TGF-β1 for 48 h.
Following treatment, cells were collected and subjected to total RNA
isolation and quantitative PCR. CAFs induced with 10 ng/ml of TGF-
β1 showed a marked increase in the expression of FNDC1, SERPINE1,
and STC2 compared to untreated control cells
Fig. 6 Immunohistochemical expression of PINP and α-SMA in
representative samples of OSCCs of this study. a Positivity for PINP
was observed mainly in the cytoplasm of the stromal cells adjacent the
tumor and in some tumor cells. b α-SMA expression was limited to
stromal cells, and α-SMA-positive cells were concentrated at the tumor
margin, immediately adjacent to the islands of tumor cells and
demarcating the invasive front of the tumor. Expression of PINP was
mainly detected in the stromal cells which were α-SMA-positive cells
(CAFs) (original magnification ×200)
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form a block containing the fibronectin III domain, which is
characterized by approximately 90 amino acids but with only
15–20 % sequence identity. In spite of this limited identity, all
fibronectin III domains have an identical protein fold, represent-
ed by a small globule with three β-strands on one side and four
on the other. This fold is similar to that of the immunoglobulin
domain, but one strand is switched to the opposite side [29].
Proteins containing this domain are thought to function as trans-
membrane receptors or cell adhesion molecules, and they can
also influence development [30]. FNDC5 (irisin), the fifth mem-
ber of the fibronectin type III domain-containing protein family,
is released into the plasma by skeletal muscles during exercise
training [30] and circulated to fat tissues where it induces a
transition to brown fat [29], suggesting an important role in
glucose metabolism. In primary central nervous system lympho-
ma, FNDC1was deleted in 41.7 % of cases and downregulation
of the mRNA levels was consistently observed. However,
FNDC1 levels were not correlated with the outcome of this
tumor [31]. Although FNDC1 was upregulated in all CAF cell
lines and TGF-β1 inducing CAF activation was followed by
increased FNDC1 expression, further analyses in human speci-
mens in association with pathway characterization are required.
SERPINE1 is a multifaceted proteolytic factor that not only
functions as an inhibitor of proteases, particularly of serine
protease urokinase plasminogen activator (uPA), but also plays
an important role in signal transduction [32]. High levels of
SERPINE1 have been consistently associated with tumor ag-
gressiveness and poor patient’s outcome [33–35]. Besides its
prognostic value, SERPINE1 expression has been validated as
a marker for therapy in patients with node-negative breast can-
cer [36, 37]. Possible mechanisms by which SERPINE1 con-
tributes to cancer dissemination include the prevention of ex-
cessive degradation of the extracellular matrix, modulation of
cell adhesion, and stimulation of angiogenesis and cell prolifer-
ation [38–40]. Immunohistochemical analysis revealed that
both SERPINE1 and α-SMA at the tumor-advancing front of
OSCCs were significantly associated with extracapsular spread
of cervical lymph nodes, a prognostic marker of OSCC out-
come, and the combination of α-SMA/SERPINE1 positivity
was significantly associated with poor survival of OSCC pa-
tients [41]. Interestingly, C-188-9, a STAT-3 inhibitor, de-
creased pulmonary fibrosis and resulted in inhibition of
fibroblast-to-myofibroblast differentiation and TGF-β-induced
expression of multiple genes including SERPINE1 [42].
Table 2 Correlation analysis of
CAF density and PINP
expression in the different







PINP—overall – 0.357 0.177 0.168
PINP—tumor front 0.001 – 0.128 0.538
CAF density—overall 0.07 0.19 – 0.777
CAF density—tumor front 0.08 0.0002 <0.0001 –
Spearman’s coefficient (rs) is above the diagonal, and p value is below diagonal
Table 3 Spearman correlation of
the clinicopathological variables
with immunohistochemical
expression of PINP and CAF
density









Age 0.285/0.002 0.071/0.45 0.021/0.84 0.032/0.76
Gender 0.027/0.78 0.097/0.31 −0.083/0.40 −0.141/0.15
Smoking habit −0.093/0.37 −0.093/0.38 −0.123/0.26 −0.011/0.91
Drinking habit −0.015/0.89 −0.005/0.96 0.038/0.74 0.117/0.32
Tumor site 0.055/0.56 0.051/0.60 −0.027/0.78 0.025/0.79
T stage 0.107/0.26 −0.021/0.82 0.169/0.08 0.125/0.20
N stage 0.107/0.26 −0.071/0.45 0.169/0.08 0.178/0.07
Treatment 0.015/0.87 −0.078/0.41 0.261/0.007 0.286/0.003
Histopathological grade 0.139/0.14 0.139/0.14 0.056/0.56 −0.031/075
Margin status 0.049/0.43 −0.002/0.98 −0.074/0.45 −0.051/0.61
Local recurrence 0.104/0.27 0.104/0.27 0.182/0.06 0.125/0.20
Regional recurrence −0.139/0.14 −0.083/0.38 0.103/0.29 0.137/0.16
Distant recurrence −0.135/0.15 0.008/0.94 0.096/0.32 −0.036/0.71
Second primary −0.107/0.26 −0.021/0.82 −0.156/0.11 −0.188/0.05
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Another protein that may support the protumoral effects of
CAFs on oral cancer cells is STC2, which we found to be
upregulated in the secretome of CAFs and in TGF-β1-
treated NOFs. STC2, a secreted glycoprotein hormone
expressed by a variety of tissues, regulates calcium and phos-
phate homeostasis, inhibits apoptosis and oxidative damage,
and induces proliferation [43, 44]. STC2 has recently been
described to inhibit epithelial-mesenchymal transition through
the PKC/claudin-1-mediated signaling in human breast cancer
cells [45]. Previous studies have shown deregulated expres-
sion of STC2 in a variety of cancers, with its expression cor-
relating with poor prognosis [45–51]. Although such studies
Fig. 7 Specific survival curves of
the OSCC patients according to
PINP expression levels and CAF
density. Specific survival was
determined by the period between
the treatment beginning until
death by the cancer or last follow-
up information. The univariate
analysis revealed that high
positivity for PINP in the stromal
cells in both overall and tumor
invasive front is significantly
associated with shortened
survival. The specific survival
according to the Kaplan-Meier
method also revealed that
abundant presence of CAFs in the
invasive tumor front is associated
with poor prognosis
Fig. 8 Expression of PINP and
density of CAFs are associated
with shortened disease-free
survival of patients with OSCC.
Disease-free survival was
calculated by the time between
initiation of treatment until
diagnosis of the recurrence (local,
regional, or distant) or last follow-
up information for those without
recurrence. Abundant presence of
CAFs in both overall stroma and
invasive tumor front was
associated with shortened
disease-free survival. Increased
PINP expression in the invasive
front was also significantly
associated with lower disease-free
survival
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have focused on STC2 expression by the tumor cells, the
immunohistochemical images clearly show that STC2 is also
expressed by mesenchymal cells adjacent to tumor islands
resembling CAFs. STC2 may thus be released by CAFs,
allowing the OSCC cells to become invasive and
prometastatic.
The results presented here also revealed that CAFs express
a variety of upregulated proteins that control collagen meta-
bolic processes. This was previously described in other studies
that investigated CAFs derived from other tumors [18, 19, 22,
52]. In a recent study, Rasanen and collaborators [20] charac-
terized the secretomes of E-cadherin low mesenchymal-like
subpopulations of OSCCs, which resembled that of CAFs,
and revealed upregulation of several proteins involved in or-
ganization of the extracellular matrix, such as multiple types
of collagen. The CAF secretome, particularly type I collagen
and its bioactive peptides derived from procollagen matura-
tion, has been associated with an invasion-permissive stroma
in ovarian, colon, and breast cancer cells [53] as well as
proangiogenic stroma [28, 54]. Interestingly, the decrease in
type I collagen expression in breast carcinoma contributes to
normalization of the tumor stroma and improves the
intratumoral penetration of therapeutics [55]. PINP immuno-
histochemical analysis, representing the procollagen fragment
of type I collagen, revealed positivity in both stromal and
tumor cells, but the intensity was lower in tumor cells com-
pared to stromal cells. Strong and positive correlations be-
tween PINP expression by stromal cells and CAFs (α-SMA-
positive cells) were observed. Furthermore, PINP expression
by stromal cells in the invasive front was significantly associ-
ated with the outcome of patients with OSCCs. The associa-
tion of abundant presence of CAFs in the invasive tumor front
with shorter overall survival was confirmed, as originally de-
scribed by us [11] and later by others [12–15]. Taken together,
our results demonstrate that expression of type I collagen by
CAFs is an indicator of outcome of OSCCs and reinforce the
suggested role of CAFs in tumor progression and metastasis.
In conclusion, cancer progression is the result of a complex
cross talk between tumor and stromal cells such as CAFs, and
an understanding of the mechanisms by which CAFs induce
tumorigenesis is essential for identification of new therapeutic
targets, as well as novel prognostic markers. In the current
study, the secretome profiling of CAFs isolated from OSCC
stroma revealed that the expression of proteins involved in
extracellular matrix organization and remodeling is altered
compared to NOFs, suggesting a possible influence in OSCC
phenotypes. FNDC1, SERPINE1, and STC2 may be impor-
tant proteins associated with CAF-induced oral cancer pro-
gression and development, although further research is war-
ranted. Moreover, induction of collagen synthesis by CAFs,
particularly type I collagen, may affect OSCC behavior, since
high levels of PINP expression by CAFs in the invasive front
were significantly associated with a worse prognosis.
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